Fox2Now St. Louis

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health ...

NEW YORK and AMSTERDAM, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient ...

AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus

AtaiBeckley (NasdaqGM: ATAI) reported peer reviewed Phase 2a results for its BPL-003 program in treatment resistant depression. The study showed a rapid and sustained antidepressant response from a ...

AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs

AtaiBeckley Inc. (NASDAQ:ATAI) secured a spot on our list of the best penny stocks set to explode. AtaiBeckley Inc.
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...
Seeking Alpha

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First ...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of ...
Benzinga.com

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
Bloomberg L.P.

Atai Shares Rise on Beckley’s Psychedelic Drug Study Success

Atai Life Sciences NV shares climbed after a psychedelic nasal spray from Beckley Psytech Ltd, the company it plans to acquire, significantly eased depression symptoms in a mid-stage trial. The study ...
Insider Monkey

Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Seeking Alpha

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Safety and efficacy results from this study support ...